In Singapore, Dupixent is the first biologic medicine approved to treat these COPD patients. The prevalence of COPD is estimated to be around 6% of the general population [1], and it ranks as a ...

FDA approves Dupixent as the first new CSU treatment in over a decade. 2. Phase 3 trial shows significant symptom reduction ...

Asthma biologics can be continued and initiated during conception, throughout pregnancy and while breastfeeding, especially ...

Q1 2025 Earnings Call Transcript May 9, 2025 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.82, expectations were $-0.92. Justine Koenigsberg: Good morning, and welcome to ...

That gives it an advantage over other biologics for severe asthma, such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab ... has attributed to complex administration and a demanding ...

the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National Medical Products Administration (NMPA), which announced its approval the same day.

swallowed topical corticosteroids taken after meals with a 30 min fasting period and dupilumab administered subcutaneously once a week). Etrasimod's simple administration, independent of meals, could ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

New biologic and targeted therapies are changing the landscape of prurigo nodularis care, offering sustained relief and ...

Current eosinophilic esophagitis treatment guidelines include dietary modifications, medications, and endoscopic procedures.

In a letter, Harvard’s president pointed to areas of agreement with the Trump administration, including a need for more “intellectual diversity.” He also argued Harvard is not partisan.

Includes Detailed Profiles of Industry Giants Eli Lilly & Company, Pfizer, Sun Pharmaceutical Industries, Arcutis Biotherapeutics, Bristol-Myers Squibb, AbbVie, Regeneron Pharmaceuticals, and Aclaris ...